Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials.

Also in this patient group, reductions in DBP at week 52 with both combination doses were marginally significant when compared with linagliptin 5 mg (both p=0.05), but did not approach statistical significance when compared with empagliflozin. 3.1.2.

also in 26,082 other papers

However, the reductions in FPG with both combinations did not reach statistical significance when compared with the empagliflozin 10-mg or empagliflozin 25-mg groups at either week 24 or week 52.

also in 111,027 other papers